Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inaticabtagene Autoleucel for MRD+ B-ALL in CR1
NCT06718244Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of inaticabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Ruijin Hospital. Started Dec 2024; status: recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06718244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06718244.